-
J. Edward Moreno
Posts
Doximity sinks on gloomy full-year revenue outlook, says AI compute costs are weighing on margins
The company reported earnings results on Wednesday.
Hims enters a “strategic pivot” following blowback from its copycat Wegovy pill
After selling compounded GLP-1 drugs for two years, Hims is launching an expensive shift to branded treatments.
Hims reports revenue miss and surprise loss in Q1
The company reported earnings results on Monday.
Lumentum jumps on Nasdaq-100 Index inclusion
The stock rose 4.8% in premarket trading by 6 a.m. ET.
Investors really want Moderna to whip up a hantavirus vaccine
The company told Bloomberg it is in the early stages of researching vaccines to protect against hantaviruses.
McDonald’s Q1 results come in above Wall Street estimates
The company reported earnings results on Thursday.
Snap ends Perplexity deal, says advertising business took a hit from “geopolitical headwinds” in Q1
The company reported earnings results on Wednesday.
Oscar Health beats Q1 estimates on lower medical costs, reaffirms full-year guidance
The company reported earnings results on Wednesday.
Stocks rally, oil falls as US and Iran reportedly close in on deal to end war
Transit restrictions on the Strait of Hormuz could be lifted as part of the agreement, per Axios.
Novo beats Q1 estimates, raises full-year guidance
The drugmaker reported earnings results on Wednesday.